These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9847012)

  • 1. Evaluation of the diagnostic performance of the Boehringer Mannheim CEDIA LSD assay.
    Verstraete AG; Steyaert S
    J Anal Toxicol; 1998; 22(7):601-4. PubMed ID: 9847012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of EMIT II, CEDIA, and DPC RIA assays for the detection of lysergic acid diethylamide in forensic urine samples.
    Wiegand RF; Klette KL; Stout PR; Gehlhausen JM
    J Anal Toxicol; 2002 Oct; 26(7):519-23. PubMed ID: 12423010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and interpretation of lysergic acid diethylamide results by immunoassay screening of urine in various testing groups.
    Wu AH; Feng YJ; Pajor A; Gornet TG; Wong SS; Forte E; Brown J
    J Anal Toxicol; 1997; 21(3):181-4. PubMed ID: 9171199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoassay analysis of lysergic acid diethylamide.
    Cody JT; Valtier S
    J Anal Toxicol; 1997 Oct; 21(6):459-64. PubMed ID: 9323526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction.
    Grobosch T; Lemm-Ahlers U
    J Anal Toxicol; 2002 Apr; 26(3):181-6. PubMed ID: 11991536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved CEDIA benzodiazepine assay eliminates sertraline crossreactivity.
    Fitzgerald RL; Herold DA
    J Anal Toxicol; 1997; 21(1):32-5. PubMed ID: 9013289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Microgenics CEDIA heroin metabolite (6-AM) and the Roche Abuscreen ONLINE opiate immunoassays for the detection of heroin use in forensic urine samples.
    Holler JM; Bosy TZ; Klette KL; Wiegand R; Jemionek J; Jacobs A
    J Anal Toxicol; 2004 Sep; 28(6):489-93. PubMed ID: 15516301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference with testing for lysergic acid diethylamide.
    Ritter D; Cortese CM; Edwards LC; Barr JL; Chung HD; Long C
    Clin Chem; 1997 Apr; 43(4):635-7. PubMed ID: 9105265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development and application of a gas chromatography-mass spectrometric (GC-MS) assay to determine the presence of 2-oxo-3-hydroxy-LSD in urine.
    Burnley BT; George S
    J Anal Toxicol; 2003; 27(4):249-52. PubMed ID: 12820748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study.
    Schwettmann L; Külpmann WR; Vidal C
    Clin Chem Lab Med; 2006; 44(4):479-87. PubMed ID: 16599844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEDIA for screening drugs of abuse in urine and the effect of adulterants.
    Wu AH; Forte E; Casella G; Sun K; Hemphill G; Foery R; Schanzenbach H
    J Forensic Sci; 1995 Jul; 40(4):614-8. PubMed ID: 7595298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. False-positive LSD testing in urine samples from intensive care patients.
    Röhrich J; Zörntlein S; Lotz J; Becker J; Kern T; Rittner C
    J Anal Toxicol; 1998 Sep; 22(5):393-5. PubMed ID: 9737335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An online immunoassay for LSD: comparison with GC-MS and the Abuscreen RIA.
    McNally AJ; Goc-Szkutnicka K; Li Z; Pilcher I; Polakowski S; Salamone SJ
    J Anal Toxicol; 1996 Oct; 20(6):404-8. PubMed ID: 8889676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated extraction of lysergic acid diethylamide (LSD) and N-demethyl-LSD from blood, serum, plasma, and urine samples using the Zymark RapidTrace with LC/MS/MS confirmation.
    de Kanel J; Vickery WE; Waldner B; Monahan RM; Diamond FX
    J Forensic Sci; 1998 May; 43(3):622-5. PubMed ID: 9608700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty.
    Mina A
    J Pharmacol Toxicol Methods; 2020; 101():106649. PubMed ID: 31730939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of lysergic acid diethylamide in human urine: elimination, screening and analytical confirmation].
    Vu-Duc T; Vernay A; Calanca A
    Schweiz Med Wochenschr; 1991 Dec; 121(50):1887-90. PubMed ID: 1759150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of LSD in urine with high-performance liquid chromatography--mass spectrometry.
    Bodin K; Svensson JO
    Ther Drug Monit; 2001 Aug; 23(4):389-93. PubMed ID: 11477321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-oxo-3-hydroxy-LSD: an important LSD metabolite?
    Verstraete AG; Van de Velde EJ
    Acta Clin Belg; 1999; 53 Suppl 1():94-6. PubMed ID: 10216992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between the CEDIA and EMIT II immunoassays for the determination of benzodiazepines.
    Way BA; Walton KG; Koenig JW; Eveland BJ; Scott MG
    Clin Chim Acta; 1998 Mar; 271(1):1-9. PubMed ID: 9564553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values.
    Fraser AD; Meatherall R
    J Anal Toxicol; 1996; 20(4):217-23. PubMed ID: 8835658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.